## Chemours (CC) — “hard-to-find in filings” deep dive (PFAS liability mechanics, hidden leverage triggers, and where the economic sensitivity really sits) ### Executive takeaway Chemours is best understood as **(1) a TiO₂ cycle business (Titanium Technologies) + (2) a regulation-driven refrigerants transition business (Thermal & Specialized Solutions) + (3) a high-performance fluoropolymer portfolio (Advanced Performance Materials)**—all wrapped in a capital structure and legacy-liability framework where **PFAS cost-sharing mechanics, escrow gates, and covenant step-ups** matter as much as near-term volume/price. ["Titanium Technologies segment"](0000950170-25-021787|0) ["Thermal & Specialized Solutions"](0000950170-25-021787|0) ["Advanced Performance Materials"](0000950170-25-021787|0) Below, I’ll surface filing details that are easy to miss even for experienced readers. --- # 1) The PFAS “operating system”: not just “risk factors,” but a *multi-layer liability plumbing* ## 1.1 The January-2021 PFAS cost-sharing MOU: what it covers, when it ends, and the $4B “cap” people misread Chemours, DuPont, Corteva, and EID entered a binding MOU to share **future legacy PFAS liabilities** tied to **pre–July 1, 2015 conduct**, lasting until the earliest of **(i) Dec 31, 2040, (ii) aggregate “Qualified Spend” = $4,000 million, or (iii) earlier termination per MOU terms**. ["binding MOU"](0000950170-23-056036|0) ["until the earlier to occur"](0000950170-23-056036|0) ["aggregate amount of Qualified Spend is equal to $4,000"](0000950170-23-056036|0) **Qualified Spend is broad**—it is not just settlements. It includes (among other things) (i) “Indemnifiable Losses” including punitive damages (to the extent connected), (ii) costs to abate/remediate/defend/settle/pay for PFAS exposure, (iii) certain fines/penalties for legacy emissions/discharges, and (iv) “Site-Related GenX Claims.” ["Qualified Spend includes"](0000950170-23-056036|0) ["Any costs or amounts to abate"](0000950170-23-056036|0) ["Fines and/or penalties"](0000950170-23-056036|0) ["Site-Related GenX Claims"](0000950170-23-056036|0) **The split:** Chemours bears **50%**, DuPont + Corteva collectively bear **50%** (up to the aggregate cap). ["Chemours will bear half"](0000950170-23-056036|0) ### Why this is “hard-to-find important” The MOU can *economically* dampen Chemours’ exposure (sharing), but it also creates a second-order risk: **disputes, interpretation fights, and “who pays what/when”**. Chemours explicitly flags that disputes about the MOU/cost-sharing could be materially adverse. ["Disputes with or among the DuPont Indemnitees"](0000950170-24-037171|0) --- ## 1.2 The escrow account: the *gating mechanism* that delays cash relief (and can surprise liquidity models) The MOU sets up an escrow account with **scheduled deposits**: - Chemours: **$100M by Sept 30, 2021** and **$100M by Sept 30, 2022**; then **$50M annually each Sept 30 through 2028** (with similar aggregate deposits from DuPont/Corteva). ["Chemours shall deposit $100"](0000950170-23-056036|0) ["no later than September 30 of each subsequent year through and including 2028"](0000950170-23-056036|0) There is also a **replenishment concept**: if balance at Dec 31, 2028 is < $700M, parties restore it via installments starting Sept 30, 2029. ["if on December 31, 2028"](0000950170-23-056036|0) ["restore the balance"](0000950170-23-056036|0) ### The key “gotcha”: withdrawal gates Escrow cannot be freely used to pay PFAS bills immediately: - **No withdrawals before January 2026**, except for mutually agreed third-party settlements in excess of $125M. ["No withdrawals are permitted"](0000950170-23-056036|0) - Starting **January 2026**, withdrawals only if **aggregate Qualified Spend in that year > $200M**. ["Starting in January 2026"](0000950170-23-056036|0) ["greater than $200"](0000950170-23-056036|0) - Starting **January 2031**, escrow can fund **any Qualified Spend**. ["Starting in January 2031"](0000950170-23-056036|0) **Interpretation:** even if the MOU exists, Chemours’ near-term cash outflows may not be offset by escrow draws until the gates open, so liquidity modeling needs to treat escrow as **restricted cash first**, not a ready liability sink. ["reflected as a transfer to restricted cash"](0000950170-23-056036|0) --- ## 1.3 “Accrued litigation” is the X-ray: watch the composition, not just the total ### Litigation accruals jumped when PFAS matters “moved from narrative to numbers” In Q3 2023, Chemours disclosed a step-change in accrued litigation, including PFAS buckets. For example, at **Sept 30, 2023** total accrued litigation was **$724M** vs **$96M** at Dec 31, 2022, with **PFAS = $633M** (separate from PFOA). ["Total accrued litigation $724"](0000950170-23-056036|0) ["PFAS (2) 633"](0000950170-23-056036|0) ["December 31, 2022 ... Total accrued litigation $96"](0000950170-23-056036|0) By **June 30, 2025**, accrued litigation is presented differently (more granular PFAS split), totaling **$497M** (Asbestos $86M; PFOA $39M; Other PFAS matters $349M; All other $23M). ["Total accrued litigation $497"](0000950170-25-103212|0) ["Other PFAS matters (3) 349"](0000950170-25-103212|0) ["PFOA (2) 39"](0000950170-25-103212|0) ### Table — Accrued litigation (selected snapshots, USD millions) | As of date | Total accrued litigation | PFAS / PFAS-related detail | |---|---:|---| | Dec 31, 2022 | 96 ["Total accrued litigation"](0000950170-23-056036|0) | PFAS = 2 ["PFAS (2)"](0000950170-23-056036|0) | | Sept 30, 2023 | 724 ["Total accrued litigation"](0000950170-23-056036|0) | PFAS = 633 ["PFAS (2)"](0000950170-23-056036|0) | | June 30, 2025 | 497 ["Total accrued litigation"](0000950170-25-103212|0) | PFOA = 39 ["PFOA (2)"](0000950170-25-103212|0) / Other PFAS = 349 ["Other PFAS matters (3)"](0000950170-25-103212|0) | **Why this matters:** the presentation changes tell you *what management believes has become estimable* and how the risk is migrating between PFAS “sub-buckets,” not just the headline total. ["Significant judgment is required"](0000950170-25-103212|0) --- ## 1.4 Regulatory standards can push liabilities higher even without “new lawsuits” Chemours explicitly ties EPA PFAS actions (e.g., proposed drinking water standards / MCLs and hazard index approach for additional PFAS including HFPO Dimer Acid) to potential increases in **environmental remediation liabilities and accrued litigation**. ["proposed a NPDWR"](0000950170-24-037171|0) ["our estimated environmental remediation liabilities and accrued litigation could increase"](0000950170-24-037171|0) --- # 2) A “quiet” risk: internal controls, incentive metrics, and governance reset after the Audit Committee Internal Review This is unusually specific in filings and directly affects credibility of KPIs like FCF. Chemours disclosed that the Audit Committee internal review found former senior management engaged in **working capital timing actions** (delaying vendor payments and accelerating receivables) partly to meet **publicly communicated free cash flow targets** and incentive-compensation metrics, with a lack of transparency to the board. ["delay payments"](0000950170-24-089414|0) ["accelerate the collection of receivables"](0000950170-24-089414|0) ["in part to meet free cash flow targets"](0000950170-24-089414|0) In 2024 Proxy disclosures, the company states the board/CLDC **used negative discretion** to reduce the former CEO/CFO’s incentive outcomes to $0 for certain plans. ["applied full negative discretion"](0001104659-24-046287|1) ["reduce the 2023 AIP awards ... to $0"](0001104659-24-046287|1) By year-end 2024, Chemours states it **remediated all four previously identified material weaknesses** and concluded ICFR effective as of Dec 31, 2024. ["successfully remediated all four"](0001104659-25-025816|0) ["internal control over financial reporting was effective"](0001104659-25-025816|0) --- # 3) The debt “control panel”: covenant step-ups, springing maturities, and why revolver availability ≠ liquidity ## 3.1 The revolver/credit agreement covenant that actually bites: senior secured net leverage maintenance test In May 2025 (Amendment No. 3), Chemours increased the **senior secured net leverage ratio** quarterly maintenance test thresholds temporarily (step-down structure): - **2.75x** for fiscal quarters ended **Mar 31, 2025 through Mar 31, 2026** - **2.50x** for quarters ended **Jun 30, 2026 and Sep 30, 2026** - back to **2.00x** for **Dec 31, 2026 and thereafter** ["increased the senior secured net leverage ratio"](0000950170-25-064546|0) ["2.75 to 1.00"](0000950170-25-064546|0) ["2.50 to 1.00"](0000950170-25-064546|0) ["2.00 to 1.00"](0000950170-25-064546|0) This is a “hard-to-notice” mechanical signal: lenders allowed more headroom **for a period**, implying the company’s leverage trajectory mattered enough to renegotiate. ## 3.2 “Springing maturity” is the hidden tripwire Post-amendment, revolving commitments are subject to springing maturity (91 days prior) if certain instruments haven’t been redeemed/refinanced/extended/replaced, including the **5.375% notes due 2027, 5.750% due 2028, 4.625% due 2029**, and term loans, etc. ["subject to springing maturity"](0000950170-25-064546|0) ["5.375% senior notes due 2027"](0000950170-25-064546|0) ["5.750% senior notes due 2028"](0000950170-25-064546|0) ["4.625% senior notes due 2029"](0000950170-25-064546|0) ## 3.3 Table — Debt maturity stack (as disclosed, USD millions) From the Q1 2025 10-Q maturity table (this is the one analysts often overlook because it includes non-debt obligations too). | Year bucket | Total (all categories shown) | |---|---:| | 2027 | 521 ["2027 ... 521"](0000950170-25-064546|0) | | 2028 | 2,270 ["2028 ... 2,270"](0000950170-25-064546|0) | | 2029 | 631 ["2029 ... 631"](0000950170-25-064546|0) | | Thereafter | 727 ["Thereafter ... 727"](0000950170-25-064546|0) | --- # 4) The real business model: segment economics + where regulation and cyclicality show up Chemours’ segments are straightforward at a high level; what’s *harder to pull out* is the **micro-mix and regulatory mechanics** inside the segments. ## 4.1 TSS: Opteon vs. Freon — the transition is visible in product-group net sales (quarterly) Chemours discloses net sales by product group inside TSS. ### Table — TSS product-group net sales (Q1 2025 vs Q1 2024, USD millions) | Product group | Q1 2025 | Q1 2024 | |---|---:|---:| | Opteon refrigerants | 279 ["OpteonTM refrigerants"](0000950170-25-064546|0) | 200 ["OpteonTM refrigerants"](0000950170-25-064546|0) | | Freon refrigerants | 97 ["FreonTM refrigerants"](0000950170-25-064546|0) | 173 ["FreonTM refrigerants"](0000950170-25-064546|0) | | Foam/propellants/other | 90 ["Foam, propellants, and other"](0000950170-25-064546|0) | 81 ["Foam, propellants, and other"](0000950170-25-064546|0) | Chemours ties Opteon volume strength to the **stationary AC transition under the U.S. AIM Act**, while Freon volumes decline with regulatory step-downs; price pressure is linked to elevated HFC inventory levels. ["stationary air conditioning original equipment manufacturer transition under the U.S. AIM Act"](0000950170-25-064546|0) ["lower volumes for Freon"](0000950170-25-064546|0) ["softer FreonTM Refrigerant portfolio pricing"](0000950170-25-064546|0) ## 4.2 Regulation is not abstract: it shows up as “quota allowance” costs and non-Corpus sourcing costs For FY2024, Chemours says TSS margin pressure was driven by softer Freon pricing plus costs including **purchasing non-Corpus low GWP refrigerant** and **near-term quota allowances**, plus lower fixed cost absorption in the HFC line. ["higher costs associated with purchasing non-Corpus based low GWP refrigerant"](0000950170-25-021787|0) ["near-term quota allowances"](0000950170-25-021787|0) ["lower fixed cost absorption"](0000950170-25-021787|0) ## 4.3 FY2024 segment snapshot (net sales + Adj. EBITDA margin) From the FY2024 10-K segment table for TSS: | Metric | FY2024 | FY2023 | |---|---:|---:| | TSS net sales (USD bn) | 1.830 ["Segment net sales"](0000950170-25-021787|0) | 1.851 ["Segment net sales"](0000950170-25-021787|0) | | TSS Adj. EBITDA margin | 31% ["Adjusted EBITDA margin"](0000950170-25-021787|0) | 37% ["Adjusted EBITDA margin"](0000950170-25-021787|0) | --- # 5) A “filings-only” geo view: where revenue is actually landing (and how it shifts) Chemours provides net sales disaggregation by **region AND segment**. ### Table — Net sales by region (Q2 2025, USD millions; customer location basis) | Region | Total net sales | |---|---:| | North America | 753 ["Total North America"](0000950170-25-103212|0) | | Asia Pacific | 334 ["Total Asia Pacific"](0000950170-25-103212|0) | | EMEA | 330 ["Total Europe, the Middle East, and Africa"](0000950170-25-103212|0) | | Latin America (incl. Mexico) | 198 ["Total Latin America"](0000950170-25-103212|0) | | **Total** | **1,615** ["Total net sales"](0000950170-25-103212|0) | --- # 6) “Interactive” map: tell me where to zoom next (no extra setup needed) Pick any module below and I’ll go one level deeper *inside the filings* (e.g., exact covenant language, specific legal matter descriptions, or segment driver bridges): 1) **PFAS playbook deep dive**: trace (a) MOU cost-sharing logic, (b) escrow gates, and (c) how each major settlement interacts with “Qualified Spend” accounting. ["Qualified Spend"](0000950170-23-056036|0) 2) **Credit agreement microscope**: springing maturity instruments + leverage covenant step-down schedule + pricing grid mechanics. ["springing maturity"](0000950170-25-064546|0) ["senior secured net leverage ratio"](0000950170-25-064546|0) 3) **TSS transition dashboard**: Opteon vs Freon economics and what AIM Act step-downs mean operationally. ["OpteonTM refrigerants"](0000950170-25-064546|0) ["U.S. AIM Act"](0000950170-25-064546|0) 4) **Governance / controls timeline**: from Audit Committee Internal Review findings → incentive clawbacks/negative discretion → remediation and ICFR effectiveness. ["Audit Committee Internal Review"](0000950170-24-089414|0) ["full negative discretion"](0001104659-24-046287|1) ["internal control ... effective"](0001104659-25-025816|0) If you want the most “alpha” next step, choose **(1) PFAS playbook** or **(2) credit agreement microscope**—those are where the filings hide the highest-impact mechanics.

## Chemours (CC) — “hard-to-find in filings” deep dive (PFAS liability mechanics, hidden leverage triggers, and where the economic sensitivity really sits) ### Executive takeaway Chemours is best understood as **(1) a TiO₂ cycle business (Titanium Technologies) + (2) a regulation-driven refrigerants transition business (Thermal & Specialized Solutions) + (3) a high-performance fluoropolymer portfolio (Advanced Performance Materials)**—all wrapped in a capital structure and legacy-liability framework where **PFAS cost-sharing mechanics, escrow gates, and covenant step-ups** matter as much as near-term volume/price. ["Titanium Technologies segment"](0000950170-25-021787|0) ["Thermal & Specialized Solutions"](0000950170-25-021787|0) ["Advanced Performance Materials"](0000950170-25-021787|0) Below, I’ll surface filing details that are easy to miss even for experienced readers. --- # 1) The PFAS “operating system”: not just “risk factors,” but a *multi-layer liability plumbing* ## 1.1 The January-2021 PFAS cost-sharing MOU: what it covers, when it ends, and the $4B “cap” people misread Chemours, DuPont, Corteva, and EID entered a binding MOU to share **future legacy PFAS liabilities** tied to **pre–July 1, 2015 conduct**, lasting until the earliest of **(i) Dec 31, 2040, (ii) aggregate “Qualified Spend” = $4,000 million, or (iii) earlier termination per MOU terms**. ["binding MOU"](0000950170-23-056036|0) ["until the earlier to occur"](0000950170-23-056036|0) ["aggregate amount of Qualified Spend is equal to $4,000"](0000950170-23-056036|0) **Qualified Spend is broad**—it is not just settlements. It includes (among other things) (i) “Indemnifiable Losses” including punitive damages (to the extent connected), (ii) costs to abate/remediate/defend/settle/pay for PFAS exposure, (iii) certain fines/penalties for legacy emissions/discharges, and (iv) “Site-Related GenX Claims.” ["Qualified Spend includes"](0000950170-23-056036|0) ["Any costs or amounts to abate"](0000950170-23-056036|0) ["Fines and/or penalties"](0000950170-23-056036|0) ["Site-Related GenX Claims"](0000950170-23-056036|0) **The split:** Chemours bears **50%**, DuPont + Corteva collectively bear **50%** (up to the aggregate cap). ["Chemours will bear half"](0000950170-23-056036|0) ### Why this is “hard-to-find important” The MOU can *economically* dampen Chemours’ exposure (sharing), but it also creates a second-order risk: **disputes, interpretation fights, and “who pays what/when”**. Chemours explicitly flags that disputes about the MOU/cost-sharing could be materially adverse. ["Disputes with or among the DuPont Indemnitees"](0000950170-24-037171|0) --- ## 1.2 The escrow account: the *gating mechanism* that delays cash relief (and can surprise liquidity models) The MOU sets up an escrow account with **scheduled deposits**: - Chemours: **$100M by Sept 30, 2021** and **$100M by Sept 30, 2022**; then **$50M annually each Sept 30 through 2028** (with similar aggregate deposits from DuPont/Corteva). ["Chemours shall deposit $100"](0000950170-23-056036|0) ["no later than September 30 of each subsequent year through and including 2028"](0000950170-23-056036|0) There is also a **replenishment concept**: if balance at Dec 31, 2028 is < $700M, parties restore it via installments starting Sept 30, 2029. ["if on December 31, 2028"](0000950170-23-056036|0) ["restore the balance"](0000950170-23-056036|0) ### The key “gotcha”: withdrawal gates Escrow cannot be freely used to pay PFAS bills immediately: - **No withdrawals before January 2026**, except for mutually agreed third-party settlements in excess of $125M. ["No withdrawals are permitted"](0000950170-23-056036|0) - Starting **January 2026**, withdrawals only if **aggregate Qualified Spend in that year > $200M**. ["Starting in January 2026"](0000950170-23-056036|0) ["greater than $200"](0000950170-23-056036|0) - Starting **January 2031**, escrow can fund **any Qualified Spend**. ["Starting in January 2031"](0000950170-23-056036|0) **Interpretation:** even if the MOU exists, Chemours’ near-term cash outflows may not be offset by escrow draws until the gates open, so liquidity modeling needs to treat escrow as **restricted cash first**, not a ready liability sink. ["reflected as a transfer to restricted cash"](0000950170-23-056036|0) --- ## 1.3 “Accrued litigation” is the X-ray: watch the composition, not just the total ### Litigation accruals jumped when PFAS matters “moved from narrative to numbers” In Q3 2023, Chemours disclosed a step-change in accrued litigation, including PFAS buckets. For example, at **Sept 30, 2023** total accrued litigation was **$724M** vs **$96M** at Dec 31, 2022, with **PFAS = $633M** (separate from PFOA). ["Total accrued litigation $724"](0000950170-23-056036|0) ["PFAS (2) 633"](0000950170-23-056036|0) ["December 31, 2022 ... Total accrued litigation $96"](0000950170-23-056036|0) By **June 30, 2025**, accrued litigation is presented differently (more granular PFAS split), totaling **$497M** (Asbestos $86M; PFOA $39M; Other PFAS matters $349M; All other $23M). ["Total accrued litigation $497"](0000950170-25-103212|0) ["Other PFAS matters (3) 349"](0000950170-25-103212|0) ["PFOA (2) 39"](0000950170-25-103212|0) ### Table — Accrued litigation (selected snapshots, USD millions) | As of date | Total accrued litigation | PFAS / PFAS-related detail | |---|---:|---| | Dec 31, 2022 | 96 ["Total accrued litigation"](0000950170-23-056036|0) | PFAS = 2 ["PFAS (2)"](0000950170-23-056036|0) | | Sept 30, 2023 | 724 ["Total accrued litigation"](0000950170-23-056036|0) | PFAS = 633 ["PFAS (2)"](0000950170-23-056036|0) | | June 30, 2025 | 497 ["Total accrued litigation"](0000950170-25-103212|0) | PFOA = 39 ["PFOA (2)"](0000950170-25-103212|0) / Other PFAS = 349 ["Other PFAS matters (3)"](0000950170-25-103212|0) | **Why this matters:** the presentation changes tell you *what management believes has become estimable* and how the risk is migrating between PFAS “sub-buckets,” not just the headline total. ["Significant judgment is required"](0000950170-25-103212|0) --- ## 1.4 Regulatory standards can push liabilities higher even without “new lawsuits” Chemours explicitly ties EPA PFAS actions (e.g., proposed drinking water standards / MCLs and hazard index approach for additional PFAS including HFPO Dimer Acid) to potential increases in **environmental remediation liabilities and accrued litigation**. ["proposed a NPDWR"](0000950170-24-037171|0) ["our estimated environmental remediation liabilities and accrued litigation could increase"](0000950170-24-037171|0) --- # 2) A “quiet” risk: internal controls, incentive metrics, and governance reset after the Audit Committee Internal Review This is unusually specific in filings and directly affects credibility of KPIs like FCF. Chemours disclosed that the Audit Committee internal review found former senior management engaged in **working capital timing actions** (delaying vendor payments and accelerating receivables) partly to meet **publicly communicated free cash flow targets** and incentive-compensation metrics, with a lack of transparency to the board. ["delay payments"](0000950170-24-089414|0) ["accelerate the collection of receivables"](0000950170-24-089414|0) ["in part to meet free cash flow targets"](0000950170-24-089414|0) In 2024 Proxy disclosures, the company states the board/CLDC **used negative discretion** to reduce the former CEO/CFO’s incentive outcomes to $0 for certain plans. ["applied full negative discretion"](0001104659-24-046287|1) ["reduce the 2023 AIP awards ... to $0"](0001104659-24-046287|1) By year-end 2024, Chemours states it **remediated all four previously identified material weaknesses** and concluded ICFR effective as of Dec 31, 2024. ["successfully remediated all four"](0001104659-25-025816|0) ["internal control over financial reporting was effective"](0001104659-25-025816|0) --- # 3) The debt “control panel”: covenant step-ups, springing maturities, and why revolver availability ≠ liquidity ## 3.1 The revolver/credit agreement covenant that actually bites: senior secured net leverage maintenance test In May 2025 (Amendment No. 3), Chemours increased the **senior secured net leverage ratio** quarterly maintenance test thresholds temporarily (step-down structure): - **2.75x** for fiscal quarters ended **Mar 31, 2025 through Mar 31, 2026** - **2.50x** for quarters ended **Jun 30, 2026 and Sep 30, 2026** - back to **2.00x** for **Dec 31, 2026 and thereafter** ["increased the senior secured net leverage ratio"](0000950170-25-064546|0) ["2.75 to 1.00"](0000950170-25-064546|0) ["2.50 to 1.00"](0000950170-25-064546|0) ["2.00 to 1.00"](0000950170-25-064546|0) This is a “hard-to-notice” mechanical signal: lenders allowed more headroom **for a period**, implying the company’s leverage trajectory mattered enough to renegotiate. ## 3.2 “Springing maturity” is the hidden tripwire Post-amendment, revolving commitments are subject to springing maturity (91 days prior) if certain instruments haven’t been redeemed/refinanced/extended/replaced, including the **5.375% notes due 2027, 5.750% due 2028, 4.625% due 2029**, and term loans, etc. ["subject to springing maturity"](0000950170-25-064546|0) ["5.375% senior notes due 2027"](0000950170-25-064546|0) ["5.750% senior notes due 2028"](0000950170-25-064546|0) ["4.625% senior notes due 2029"](0000950170-25-064546|0) ## 3.3 Table — Debt maturity stack (as disclosed, USD millions) From the Q1 2025 10-Q maturity table (this is the one analysts often overlook because it includes non-debt obligations too). | Year bucket | Total (all categories shown) | |---|---:| | 2027 | 521 ["2027 ... 521"](0000950170-25-064546|0) | | 2028 | 2,270 ["2028 ... 2,270"](0000950170-25-064546|0) | | 2029 | 631 ["2029 ... 631"](0000950170-25-064546|0) | | Thereafter | 727 ["Thereafter ... 727"](0000950170-25-064546|0) | --- # 4) The real business model: segment economics + where regulation and cyclicality show up Chemours’ segments are straightforward at a high level; what’s *harder to pull out* is the **micro-mix and regulatory mechanics** inside the segments. ## 4.1 TSS: Opteon vs. Freon — the transition is visible in product-group net sales (quarterly) Chemours discloses net sales by product group inside TSS. ### Table — TSS product-group net sales (Q1 2025 vs Q1 2024, USD millions) | Product group | Q1 2025 | Q1 2024 | |---|---:|---:| | Opteon refrigerants | 279 ["OpteonTM refrigerants"](0000950170-25-064546|0) | 200 ["OpteonTM refrigerants"](0000950170-25-064546|0) | | Freon refrigerants | 97 ["FreonTM refrigerants"](0000950170-25-064546|0) | 173 ["FreonTM refrigerants"](0000950170-25-064546|0) | | Foam/propellants/other | 90 ["Foam, propellants, and other"](0000950170-25-064546|0) | 81 ["Foam, propellants, and other"](0000950170-25-064546|0) | Chemours ties Opteon volume strength to the **stationary AC transition under the U.S. AIM Act**, while Freon volumes decline with regulatory step-downs; price pressure is linked to elevated HFC inventory levels. ["stationary air conditioning original equipment manufacturer transition under the U.S. AIM Act"](0000950170-25-064546|0) ["lower volumes for Freon"](0000950170-25-064546|0) ["softer FreonTM Refrigerant portfolio pricing"](0000950170-25-064546|0) ## 4.2 Regulation is not abstract: it shows up as “quota allowance” costs and non-Corpus sourcing costs For FY2024, Chemours says TSS margin pressure was driven by softer Freon pricing plus costs including **purchasing non-Corpus low GWP refrigerant** and **near-term quota allowances**, plus lower fixed cost absorption in the HFC line. ["higher costs associated with purchasing non-Corpus based low GWP refrigerant"](0000950170-25-021787|0) ["near-term quota allowances"](0000950170-25-021787|0) ["lower fixed cost absorption"](0000950170-25-021787|0) ## 4.3 FY2024 segment snapshot (net sales + Adj. EBITDA margin) From the FY2024 10-K segment table for TSS: | Metric | FY2024 | FY2023 | |---|---:|---:| | TSS net sales (USD bn) | 1.830 ["Segment net sales"](0000950170-25-021787|0) | 1.851 ["Segment net sales"](0000950170-25-021787|0) | | TSS Adj. EBITDA margin | 31% ["Adjusted EBITDA margin"](0000950170-25-021787|0) | 37% ["Adjusted EBITDA margin"](0000950170-25-021787|0) | --- # 5) A “filings-only” geo view: where revenue is actually landing (and how it shifts) Chemours provides net sales disaggregation by **region AND segment**. ### Table — Net sales by region (Q2 2025, USD millions; customer location basis) | Region | Total net sales | |---|---:| | North America | 753 ["Total North America"](0000950170-25-103212|0) | | Asia Pacific | 334 ["Total Asia Pacific"](0000950170-25-103212|0) | | EMEA | 330 ["Total Europe, the Middle East, and Africa"](0000950170-25-103212|0) | | Latin America (incl. Mexico) | 198 ["Total Latin America"](0000950170-25-103212|0) | | **Total** | **1,615** ["Total net sales"](0000950170-25-103212|0) | --- # 6) “Interactive” map: tell me where to zoom next (no extra setup needed) Pick any module below and I’ll go one level deeper *inside the filings* (e.g., exact covenant language, specific legal matter descriptions, or segment driver bridges): 1) **PFAS playbook deep dive**: trace (a) MOU cost-sharing logic, (b) escrow gates, and (c) how each major settlement interacts with “Qualified Spend” accounting. ["Qualified Spend"](0000950170-23-056036|0) 2) **Credit agreement microscope**: springing maturity instruments + leverage covenant step-down schedule + pricing grid mechanics. ["springing maturity"](0000950170-25-064546|0) ["senior secured net leverage ratio"](0000950170-25-064546|0) 3) **TSS transition dashboard**: Opteon vs Freon economics and what AIM Act step-downs mean operationally. ["OpteonTM refrigerants"](0000950170-25-064546|0) ["U.S. AIM Act"](0000950170-25-064546|0) 4) **Governance / controls timeline**: from Audit Committee Internal Review findings → incentive clawbacks/negative discretion → remediation and ICFR effectiveness. ["Audit Committee Internal Review"](0000950170-24-089414|0) ["full negative discretion"](0001104659-24-046287|1) ["internal control ... effective"](0001104659-25-025816|0) If you want the most “alpha” next step, choose **(1) PFAS playbook** or **(2) credit agreement microscope**—those are where the filings hide the highest-impact mechanics.